poisar

Stocks · News reference

AEON Biopharma shares are trading higher after the company reported pilot study results showing its ABP‑450 had comparable potency loss and oxidation patterns to Botox under thermal and oxidative stress.

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading